Recalcitrant hypercalcemia in a dialysis patient: Case report, literature review, and proposed management algorithm

被引:0
作者
Fong, Jie Ming Nigel [1 ]
Chia, Eik Chao [2 ]
Zhang, Meifen [3 ]
Malakar, Roy Debajyoti [4 ,5 ]
机构
[1] Singapore Gen Hosp, Dept Renal Med, Singapore, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore
[3] Changi Gen Hosp, Dept Endocrinol, Singapore, Singapore
[4] Changi Gen Hosp, Dept Renal Med, Singapore, Singapore
[5] Changi Gen Hosp, Dept Renal Med, 2 Simei St 3, Singapore 529889, Singapore
关键词
BONE METASTASES; DENOSUMAB; HEMODIALYSIS; IMMOBILIZATION; ELIMINATION; PAMIDRONATE;
D O I
10.1111/sdi.13137
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A 62-year-old male on maintenance hemodialysis, who was bedbound after a cerebrovascular accident, developed progressive hypercalcemia during a prolonged hospital stay. The etiology of hypercalcemia was attributed to immobility after extensive workup including imaging for malignancy or granulomatous disease, parathyroid hormone levels, parathyroid hormone related peptide, and vitamin D levels were unyielding. Low calcium dialysate would transiently reduce serum calcium levels, but levels would rebound in the interdialytic period. In view of recalcitrant hypercalcemia presenting with crisis, denosumab was successfully used to lower serum calcium. We review the literature and propose a management algorithm for severe hypercalcemia in a patient on dialysis.
引用
收藏
页码:170 / 174
页数:5
相关论文
共 15 条
[1]   Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study [J].
Bergner, R ;
Dill, K ;
Boerner, D ;
Uppenkamp, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (07) :1281-1285
[2]   Elimination and clearance of pamidronate by haemodialysis [J].
Buttazzoni, Mirena ;
Diez, Guillermo J. Rosa ;
Jager, Victor ;
Crucelegui, Maria S. ;
Algranati, Salomon L. ;
Plantalech, Luisa .
NEPHROLOGY, 2006, 11 (03) :197-200
[3]   Calcium free hemodialysis: Experience in the treatment of 33 patients with severe hypercalcemia [J].
Camus, C ;
Charasse, C ;
JouannicMontier, I ;
Seguin, P ;
Tulzo, YL ;
Bouget, J ;
Thomas, R .
INTENSIVE CARE MEDICINE, 1996, 22 (02) :116-121
[4]  
Dahmani O, 2017, SAUDI J KIDNEY DIS T, V28, P154, DOI 10.4103/1319-2442.198239
[5]   Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety [J].
Gopaul, Aquila ;
Kanagalingam, Tharsan ;
Thain, Jenny ;
Khan, Tayyab ;
Cowan, Andrea ;
Sultan, Nabil ;
Clemens, Kristin K. .
ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
[6]   Foreword [J].
Eckardt, Kai-Uwe ;
Kasiske, Bertram L. .
KIDNEY INTERNATIONAL, 2009, 76 :S1-S2
[7]   Denosumab for dialysis patients with osteoporosis: A cohort study [J].
Kunizawa, Kyohei ;
Hiramatsu, Rikako ;
Hoshino, Junichi ;
Mizuno, Hiroki ;
Ozawa, Yuko ;
Sekine, Akinari ;
Kawada, Masahiro ;
Sumida, Keiichi ;
Hasegawa, Eiko ;
Yamanouchi, Masayuki ;
Hayami, Noriko ;
Suwabe, Tatsuya ;
Sawa, Naoki ;
Ubara, Yoshifumi ;
Takaichi, Kenmei .
SCIENTIFIC REPORTS, 2020, 10 (01) :2496
[8]   Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report [J].
Mahmoud, Sara ;
Mitwally, Hassan ;
El Zeer, Hani Soliman ;
El Madhoun, Ihab ;
Khatib, Mohamad .
AMERICAN JOURNAL OF CASE REPORTS, 2018, 19 :1087-1089
[9]  
Manandhar S., 2017, AACE CLIN CASE REP, V3, pe116, DOI [10.4158/EP161270.CR, DOI 10.4158/EP161270.CR]
[10]   Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism [J].
Pratt, Ryan M. ;
West, Michael L. ;
Tennankore, Karthik K. .
PERITONEAL DIALYSIS INTERNATIONAL, 2020, 40 (01) :103-106